FDA Clears Path for Generic Cabazitaxel After Safety Review

The FDA has determined that the prostate cancer treatment cabazitaxel was not withdrawn from sale due to safety or effectiveness concerns. This regulatory decision clears the path for the agency to approve abbreviated new drug applications for generic versions, potentially increasing patient access and affordability for this important medication.